These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 39219052)

  • 1. Targeting proliferating cell nuclear antigen enhances ionizing radiation-induced cytotoxicity in prostate cancer cells.
    Lu S; Lamba M; Wang J; Dong Z
    Prostate; 2024 Dec; 84(16):1456-1467. PubMed ID: 39219052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Additive effects of a small molecular PCNA inhibitor PCNA-I1S and DNA damaging agents on growth inhibition and DNA damage in prostate and lung cancer cells.
    Lu S; Dong Z
    PLoS One; 2019; 14(10):e0223894. PubMed ID: 31600334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proliferating cell nuclear antigen directly interacts with androgen receptor and enhances androgen receptor‑mediated signaling.
    Lu S; Dong Z
    Int J Oncol; 2021 Jul; 59(1):. PubMed ID: 33982774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Castration-resistant prostate cancer: Androgen receptor inactivation induces telomere DNA damage, and damage response inhibition leads to cell death.
    Reddy V; Iskander A; Hwang C; Divine G; Menon M; Barrack ER; Reddy GP; Kim SH
    PLoS One; 2019; 14(5):e0211090. PubMed ID: 31083651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multimodal actions of the phytochemical sulforaphane suppress both AR and AR-V7 in 22Rv1 cells: Advocating a potent pharmaceutical combination against castration-resistant prostate cancer.
    Khurana N; Kim H; Chandra PK; Talwar S; Sharma P; Abdel-Mageed AB; Sikka SC; Mondal D
    Oncol Rep; 2017 Nov; 38(5):2774-2786. PubMed ID: 28901514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor.
    Patki M; Huang Y; Ratnam M
    Biochem Biophys Res Commun; 2016 Jul; 476(2):69-74. PubMed ID: 27179779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.
    Hoang DT; Iczkowski KA; Kilari D; See W; Nevalainen MT
    Oncotarget; 2017 Jan; 8(2):3724-3745. PubMed ID: 27741508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melatonin Inhibits Androgen Receptor Splice Variant-7 (AR-V7)-Induced Nuclear Factor-Kappa B (NF-κB) Activation and NF-κB Activator-Induced AR-V7 Expression in Prostate Cancer Cells: Potential Implications for the Use of Melatonin in Castration-Resistant Prostate Cancer (CRPC) Therapy.
    Liu VWS; Yau WL; Tam CW; Yao KM; Shiu SYW
    Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28561752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination treatment with docetaxel and histone deacetylase inhibitors downregulates androgen receptor signaling in castration-resistant prostate cancer.
    Park SE; Kim HG; Kim DE; Jung YJ; Kim Y; Jeong SY; Choi EK; Hwang JJ; Kim CS
    Invest New Drugs; 2018 Apr; 36(2):195-205. PubMed ID: 29110173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the fibroblast growth factor pathway in molecular subtypes of castration-resistant prostate cancer.
    Labrecque MP; Brown LG; Coleman IM; Nguyen HM; Dalrymple S; Brennen WN; Isaacs JT; Li D; Lakely B; DeLucia DC; Lee JK; Schweizer MT; Lin DW; Corey E; Nelson PS; Morrissey C
    Prostate; 2024 Jan; 84(1):100-110. PubMed ID: 37796107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
    Thamilselvan V; Menon M; Thamilselvan S
    Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth.
    Yamamoto Y; Loriot Y; Beraldi E; Zhang F; Wyatt AW; Al Nakouzi N; Mo F; Zhou T; Kim Y; Monia BP; MacLeod AR; Fazli L; Wang Y; Collins CC; Zoubeidi A; Gleave M
    Clin Cancer Res; 2015 Apr; 21(7):1675-87. PubMed ID: 25634993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant AR
    Wu Z; Wang K; Yang Z; Pascal LE; Nelson JB; Takubo K; Wipf P; Wang Z
    Prostate; 2020 Mar; 80(4):319-328. PubMed ID: 31868960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.
    Welti J; Rodrigues DN; Sharp A; Sun S; Lorente D; Riisnaes R; Figueiredo I; Zafeiriou Z; Rescigno P; de Bono JS; Plymate SR
    Eur Urol; 2016 Oct; 70(4):599-608. PubMed ID: 27117751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor effects of a novel small molecule targeting PCNA chromatin association in prostate cancer.
    Dillehay KL; Lu S; Dong Z
    Mol Cancer Ther; 2014 Dec; 13(12):2817-26. PubMed ID: 25253786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Catalytic inhibitors of DNA topoisomerase II suppress the androgen receptor signaling and prostate cancer progression.
    Li H; Xie N; Gleave ME; Dong X
    Oncotarget; 2015 Aug; 6(24):20474-84. PubMed ID: 26009876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MYO6 contributes to tumor progression and enzalutamide resistance in castration-resistant prostate cancer by activating the focal adhesion signaling pathway.
    Zheng S; Hong Z; Tan Y; Wang Y; Li J; Zhang Z; Feng T; Hong Z; Lin G; Ye D
    Cell Commun Signal; 2024 Oct; 22(1):517. PubMed ID: 39449086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PLCε knockdown enhances the radiosensitivity of castration‑resistant prostate cancer via the AR/PARP1/DNA‑PKcs axis.
    Pu J; Li T; Liu N; Luo C; Quan Z; Li L; Wu X
    Oncol Rep; 2020 May; 43(5):1397-1412. PubMed ID: 32323799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A small molecule inhibitor of monoubiquitinated Proliferating Cell Nuclear Antigen (PCNA) inhibits repair of interstrand DNA cross-link, enhances DNA double strand break, and sensitizes cancer cells to cisplatin.
    Inoue A; Kikuchi S; Hishiki A; Shao Y; Heath R; Evison BJ; Actis M; Canman CE; Hashimoto H; Fujii N
    J Biol Chem; 2014 Mar; 289(10):7109-7120. PubMed ID: 24474685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor effects of pyrrole-imidazole polyamide modified with alkylating agent on prostate cancer cells.
    Funakoshi D; Obinata D; Fujiwara K; Yamamoto S; Takayama K; Hara M; Takahashi S; Inoue S
    Biochem Biophys Res Commun; 2022 Oct; 623():9-16. PubMed ID: 35868070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.